Phase 4
N=106
Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System
Menorrhagia
Bottom Line
View on ClinicalTrials.gov: NCT00094536 ↗Enrolled (actual)
106
Serious AEs
23.2%
Results posted
Mar 2017
Primary outcome: Primary: Success (Reduction in Menstruation to Normal Levels) — 59 Participants — p=.271
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Extended treatment regimen using Her Option Cryotherapy (Device)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- Female
- Sponsor
- CooperSurgical Inc.
- Primary completion
- Oct 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Success (Reduction in Menstruation to Normal Levels) |
59 | .271 |
Summary
The Her Option® Cryoablation Therapy System is a closed-loop cryosurgical device that is used to ablate the endometrial lining in pre-menopausal women with menorrhagia (excessive menstrual bleeding) due to benign causes. This is a non-incisional procedure, which can be performed in a physicians office with minimal sedation.
Initial FDA clinical studies were conducted with a two-freeze treatment pattern consisting of a 4 minute freeze with the Cryoprobe positioned in one cornu followed by a second freeze of 6 minutes with the Cryoprobe repositioned in the contralateral cornu.
Since completion of the early studies, many physicians have experimented with varying freeze patterns using longer freeze durations and/or additional freezes at the fundus and the lower uterine segment. The results, as reported in the literature, indicate that these extended freeze patterns produce significantly better results than the original regimen.
Eligibility Criteria
Inclusion Criteria
- Pre-menopausal adult women 30 years of age or older who have completed childbearing
- Heavy or prolonged menstrual bleeding
- Willing and able to complete all follow-up exams as required by protocol
Exclusion Criteria
- Known or suspected endometrial cancer or pre-malignant change of the endometrium
- Untreated cervical dysplasia
- Hereditary malformations of the uterine cavity that would prevent insertion and/or placement of the cryoprobe
- Uterine myomas > or = to 3 cm in diameter
- Past history of invasive treatment for abnormal uterine bleeding or uterine myomas
- History of classical (not low transverse incision) cesarean section
- Active genital or urinary tract infection or acute pelvic inflammatory disease (PID)
- Intrauterine device (IUD) in place
- Other medical conditions could be exclusionary upon evaluation for study treatment
Data sourced from ClinicalTrials.gov (NCT00094536). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.